Business Context and Reporting Period
This Form 8-K was filed by Assembly Biosciences, Inc. on June 12, 2020, reporting a material event occurring on that date. The filing addresses the termination of a significant strategic partnership.
Key Financial Metrics and Agreement Terms
The filing details the financial structure of the terminated Collaboration Agreement with Allergan Pharmaceuticals International Limited (AbbVie):
- Upfront Payment Received: $50.0 million (paid in February 2017).
- Development Milestones: Up to approximately $631.0 million for seven milestones.
- Commercial Milestones: Up to approximately $2.14 billion for 12 milestones.
- Cost Sharing: Development costs up to $75.0 million were shared on a 50/50 basis through proof-of-concept studies; post-POC costs were to be assumed by Allergan.
The filing does not provide current revenue, profit, cash flow, or debt figures for the reporting period.
Material Changes
On June 12, 2020, AbbVie notified the Company of its decision to terminate the Collaboration Agreement. Key aspects of this change include:
- Reason for Termination: A strategic portfolio decision by AbbVie, explicitly unrelated to efficacy, safety, or data from the collaboration program.
- Effective Date: The termination will become effective 120 days after notice, on October 10, 2020.
- Asset Recovery: The Company will regain worldwide rights to all licensed microbiome gastrointestinal programs, specifically ABI-M201 (Phase 1b trial for ulcerative colitis) and ABI-M301 (preclinical program for Crohn's disease).
Outlook, Risks, and Management Commentary
Management commentary indicates that the termination was driven by the partner's strategic portfolio decisions rather than scientific failure. The primary risk associated with this event is the loss of potential future milestone payments totaling over $2.7 billion and the cessation of cost-sharing for development. However, the Company retains full control and rights to the underlying programs, allowing for the pursuit of alternative commercialization strategies.
Investor Verification Checklist
- Verify the status of the Phase 1b trial for ABI-M201 and the preclinical development of ABI-M301 now that the Company has regained full rights.
- Assess the Company's current cash runway and capital requirements to fund the development of these programs independently without AbbVie's cost-sharing.
- Review the Company's strategy for re-licensing or co-promoting the regained assets in the United States and China.
- Confirm if any termination fees or additional payments are due to the Company under the agreement terms beyond the initial $50.0 million.